Baidu
map

Mol Pharmacol:研究人员发现双酚A对钙离子通道的不利影响

2013-05-06 Beyond 生物谷

许多人工合成产品中发现的一种物质双酚A被认为是有害的,特别是对胎儿和婴儿。波恩大学研究人员在实验中已经表明这种环境化学物质能阻断人类和小鼠的组织细胞膜上的钙离子通道。研究结果发表在Molecular Pharmacology杂志上。 工业化学品双酚A(BPA)是全世界广泛用于制造聚碳酸酯树脂和合成树脂的材料。这种物质已被证明会影响内分泌系统,对酶和载体蛋白的功能可能产生负面影响。 BPA与心脏

许多人工合成产品中发现的一种物质双酚A被认为是有害的,特别是对胎儿和婴儿。波恩大学研究人员在实验中已经表明这种环境化学物质能阻断人类和小鼠的组织细胞膜上的钙离子通道。研究结果发表在Molecular Pharmacology杂志上。

工业化学品双酚A(BPA)是全世界广泛用于制造聚碳酸酯树脂和合成树脂的材料。这种物质已被证明会影响内分泌系统,对酶和载体蛋白的功能可能产生负面影响。

BPA与心脏病,糖尿病,肥胖,癌症和神经功能障碍相关。胎儿和新生儿对BPA特别敏感。由于其不可预测的影响,2011年欧盟委员会婴儿奶瓶禁止使用BPA。

研究人员现在报告说,双酚A阻断多个必需的钙离子通道,BPA能可逆性地阻断小鼠和人类细胞的钙通道。

钙离子流经这些孔状的蛋白通道进入活细胞,例如控制心脏肌肉细胞,酶的活性以及​​神经细胞的收缩。新研究表明,BPA的确可以对人体健康产生不利影响。由于双酚A是可逆的结合钙通道,研究人员相信该物质至少有从体内被清楚的可能性。

doi:10.1124/mol.112.081372
PMC:
PMID:

Bisphenol A Inhibits Voltage-activated Ca2+ channels In Vitro: Mechanisms and Structural Requirements

Andre Deutschmann1, Michael Hans1, et al.

Bisphenol A (BPA), a high volume production chemical compound attracts growing attention as health relevant xenobiotic in humans. It can directly bind to hormone receptors, enzymes and ion channels to become biologically active. In this study we show that BPA acts as a potent blocker of voltage-activated Ca2+channels. We determined the mechanisms of block and the structural elements of BPA essential for its action. Macroscopic Ba2+/ Ca2+currents through native L-, N-, P/Q-, T-type Ca2+channels in rat endocrine GH3 cells, mouse DRG neurons or cardiac myocytes and recombinant human R-type Ca2+channels expressed in HEK293 cells were rapidly and reversibly inhibited by BPA with similar potency (EC50 values: 26 to 35 μM). Pharmacological and biophysical analysis of R-type Ca2+ channels revealed that BPA interacts with the extracellular part of the channel protein. Its action does not require intracellular signaling pathways, is neither voltage- nor use-dependent and does not affect channel gating. This indicates that BPA interacts with the channel in its resting state by directly binding to an external site outside the pore forming region. Structure-effect analyses of various phenolic and bisphenolic compounds revealed that (i) a double-alkylated (R-C(CH3)2-R, R-C(CH3)(CH2CH3)-R), or double-trifluoromethylated sp3 hybridized carbon atom between the two aromatic rings and (ii) the two aromatic moieties in angulated orientation are optimal for BPA's effectiveness. Since BPA highly pollutes the environment and is incorporated into the human organism our data may provide a basis for future studies relevant for human health and development.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908153, encodeId=6b741908153d2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 18 09:56:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995880, encodeId=b8401995880fc, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jul 02 08:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787130, encodeId=e3ea1e87130ec, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Apr 08 19:56:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907420, encodeId=47d1190e420c6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Jul 06 21:56:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687228, encodeId=7a41168e228a2, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Thu May 16 07:56:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788144, encodeId=6c911e88144fb, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Dec 14 14:56:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350092, encodeId=f974135009246, content=<a href='/topic/show?id=dbd33e6226c' target=_blank style='color:#2F92EE;'>#双酚A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37622, encryptionId=dbd33e6226c, topicName=双酚A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630396, encodeId=e4d51630396f6, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908153, encodeId=6b741908153d2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 18 09:56:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995880, encodeId=b8401995880fc, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jul 02 08:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787130, encodeId=e3ea1e87130ec, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Apr 08 19:56:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907420, encodeId=47d1190e420c6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Jul 06 21:56:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687228, encodeId=7a41168e228a2, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Thu May 16 07:56:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788144, encodeId=6c911e88144fb, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Dec 14 14:56:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350092, encodeId=f974135009246, content=<a href='/topic/show?id=dbd33e6226c' target=_blank style='color:#2F92EE;'>#双酚A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37622, encryptionId=dbd33e6226c, topicName=双酚A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630396, encodeId=e4d51630396f6, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-07-02 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908153, encodeId=6b741908153d2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 18 09:56:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995880, encodeId=b8401995880fc, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jul 02 08:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787130, encodeId=e3ea1e87130ec, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Apr 08 19:56:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907420, encodeId=47d1190e420c6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Jul 06 21:56:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687228, encodeId=7a41168e228a2, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Thu May 16 07:56:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788144, encodeId=6c911e88144fb, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Dec 14 14:56:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350092, encodeId=f974135009246, content=<a href='/topic/show?id=dbd33e6226c' target=_blank style='color:#2F92EE;'>#双酚A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37622, encryptionId=dbd33e6226c, topicName=双酚A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630396, encodeId=e4d51630396f6, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2014-04-08 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908153, encodeId=6b741908153d2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 18 09:56:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995880, encodeId=b8401995880fc, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jul 02 08:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787130, encodeId=e3ea1e87130ec, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Apr 08 19:56:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907420, encodeId=47d1190e420c6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Jul 06 21:56:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687228, encodeId=7a41168e228a2, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Thu May 16 07:56:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788144, encodeId=6c911e88144fb, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Dec 14 14:56:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350092, encodeId=f974135009246, content=<a href='/topic/show?id=dbd33e6226c' target=_blank style='color:#2F92EE;'>#双酚A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37622, encryptionId=dbd33e6226c, topicName=双酚A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630396, encodeId=e4d51630396f6, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908153, encodeId=6b741908153d2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 18 09:56:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995880, encodeId=b8401995880fc, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jul 02 08:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787130, encodeId=e3ea1e87130ec, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Apr 08 19:56:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907420, encodeId=47d1190e420c6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Jul 06 21:56:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687228, encodeId=7a41168e228a2, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Thu May 16 07:56:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788144, encodeId=6c911e88144fb, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Dec 14 14:56:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350092, encodeId=f974135009246, content=<a href='/topic/show?id=dbd33e6226c' target=_blank style='color:#2F92EE;'>#双酚A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37622, encryptionId=dbd33e6226c, topicName=双酚A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630396, encodeId=e4d51630396f6, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1908153, encodeId=6b741908153d2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 18 09:56:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995880, encodeId=b8401995880fc, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jul 02 08:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787130, encodeId=e3ea1e87130ec, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Apr 08 19:56:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907420, encodeId=47d1190e420c6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Jul 06 21:56:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687228, encodeId=7a41168e228a2, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Thu May 16 07:56:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788144, encodeId=6c911e88144fb, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Dec 14 14:56:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350092, encodeId=f974135009246, content=<a href='/topic/show?id=dbd33e6226c' target=_blank style='color:#2F92EE;'>#双酚A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37622, encryptionId=dbd33e6226c, topicName=双酚A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630396, encodeId=e4d51630396f6, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1908153, encodeId=6b741908153d2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 18 09:56:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995880, encodeId=b8401995880fc, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jul 02 08:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787130, encodeId=e3ea1e87130ec, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Apr 08 19:56:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907420, encodeId=47d1190e420c6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Jul 06 21:56:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687228, encodeId=7a41168e228a2, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Thu May 16 07:56:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788144, encodeId=6c911e88144fb, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Dec 14 14:56:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350092, encodeId=f974135009246, content=<a href='/topic/show?id=dbd33e6226c' target=_blank style='color:#2F92EE;'>#双酚A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37622, encryptionId=dbd33e6226c, topicName=双酚A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630396, encodeId=e4d51630396f6, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-05-08 zhaojie88
  8. [GetPortalCommentsPageByObjectIdResponse(id=1908153, encodeId=6b741908153d2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 18 09:56:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995880, encodeId=b8401995880fc, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jul 02 08:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787130, encodeId=e3ea1e87130ec, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Apr 08 19:56:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907420, encodeId=47d1190e420c6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Jul 06 21:56:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687228, encodeId=7a41168e228a2, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Thu May 16 07:56:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788144, encodeId=6c911e88144fb, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Dec 14 14:56:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350092, encodeId=f974135009246, content=<a href='/topic/show?id=dbd33e6226c' target=_blank style='color:#2F92EE;'>#双酚A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37622, encryptionId=dbd33e6226c, topicName=双酚A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630396, encodeId=e4d51630396f6, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]

相关资讯

中国人双酚A暴露水平与低度蛋白尿风险相关

    上海交通大学医学院附属瑞金医院宁光教授领导的研究团队通过大样本人群研究,首次对中国成人双酚A暴露水平与低度蛋白尿风险的相关性进行了探讨。近日,相关研究结果发表于《国际肾脏》杂志(Kidney Int. 2012 Jun;81(11):1131-9.)。     据了解,双酚A是一种广泛用于塑料制品行业的工业化学物质,常被用于食物容器、奶瓶、微波炉专用产品以

PLoS ONE:双酚A的真正威胁

对于双酚A,近年来相关的研究已指出,BPA接触与癌症、神经性障碍、生理缺陷,甚至儿童肥胖等多种健康和发育问题之间存在着惊人的关联性,能导致线虫不育,破坏生殖系统,影响基因表达,干扰乳腺癌药物疗效等等问题,已成为健康的一大威胁。调查显示,90%以上的美国人均不同程度地携带有BPA,这会给人类健康带来怎样的威胁了?下面我们先了解一下雌激素信号通路。 在人体内,有三大雌激素,雌二醇是其中之一,雌二醇或

塑料用品易引发白蛋白尿

    双酚A 是一种广泛用于塑料制品行业的工业化学物质,常被用来生产聚碳酸酯塑料和环氧树脂,水瓶和很多食品容器中均含有双酚A。近期,上海交通大学医学院附属瑞金医院内分泌代谢科宁光教授等开展的一项研究表明,长期接触双酚A 可致低水平白蛋白尿(尿白蛋白肌酐比值为9.71~29.9 mg/g)风险增加。(Kidney Int. 2012 Mar 7.)    

Epidemiology:尿双酚A或增高国人甲亢风险

  动物实验发现双酚A可与甲状腺激素受体结合从而影响甲状腺功能,但这种关联性研究尚未在人群中展开。为了探讨中国人群中尿双酚A与甲状腺功能的关系,我国上海交通大学医学院附属瑞金医院宁光教授开展了一项横断面研究。研究发现,高水平的尿双酚A与甲状腺功能亢进相关。研究于2013年1月18日在线发表于《流行病学》(Epidemiology)杂志。   该研究在上海市宝山区淞南社区招募志愿者,从2009年1

网传购物小票中物质致癌 专家称不属实

近日,网络上一条有关 含有“双酚A”超市购物小票会致癌的消息引起网友关注。消息称,购物小票、甚至出租车票中含有双酚A,可通过皮肤渗入人体内,影响人的生殖系统并致癌。对于普通消费者来说,购物小票是几乎每天都会接触的物品,这一传闻是真实的吗?8月28日,山东中医药大学附属医院肿瘤科医师王志鹏和太原师范学院化学系教授李鹏鸽接受新华网记者专访,解答网友的关切。   双酚A是被获许添加使用的

Kidney. Int:宁光等发现塑料用品易引发白蛋白尿

近期,上海交通大学医学院附属瑞金医院内分泌代谢科宁光教授等开展的一项研究表明,长期接触双酚A 可致低水平白蛋白尿(尿白蛋白肌酐比值为9.71~29.9 mg/g)风险增加。相关论文发表在Kidney International杂志上。 双酚A 是一种广泛用于塑料制品行业的工业化学物质,常被用来生产聚碳酸酯塑料和环氧树脂,水瓶和很多食品容器中均含有双酚A。 该研究纳入上海3455 例年龄≥ 40

Baidu
map
Baidu
map
Baidu
map